1O' Mallty T, Ludlam CA, Riemerrnsa RA, et al. Early increase in levels of soluble inter-cellalar adhesion molecule-l(sICAM-1) ;potential risk factor for the acute coronary syndromes [ J ]. Eur Heart J, 2001,22 (14) :1226-1234.
2de-Winter R J, Fischer J, Bholasingh R. C-reactive protein and cardiac troponin T in risk stratification: diferences in optimal timing oftests early after the onset of chest pain[J]. Clin Chem,2000,46(10) : 1597-- 1603.
3de-Winter R J, Fischer JC, de-Jongh T, et al. Different time frames for the occmrence of elevated levels of cardiac troponin T and C-reactive protein in patients with acute myocardial infarction [J]. Clin Chern Lab Med,2000,38(11) : 1151-- 1153.
4Chandra HR, Choudhaty N, O' Neill C, et al. Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome(CIMACS) [ J ]. Am J Cardiol, 2001,88(3) :214--218.
5Deckers JW. Smoking and survival in acute coronary syndrome: the fog is clearing[J]. Eur Heart J ,2001,22(9):.724-726.
6Thompson PL. Clinical relevance of statins: instituting treatment early in acute coronary syndrome patients[ J ]. At hero.let Suppl, 2001,2 ( 1 ) : 15-- 19.
7Schwartz CG, Olssoo AG, Ezekowitz MD, et al. Effects of atorvas tatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial[J]. JAMA, 2001,2S5(13) : 1711-1718.
8Amtz HR, Agawal R,Wunderlich W,et al. Beneficial effects of pravastatin ( +/-colestyrarnine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease[ L-CAD] Study) [J ]. Am J Cardiol,2000,86(12) : 1293-- 1298.
10Con AH, Igtaszewski A,Gin K. The evaluation of physician patterns of practice in cardiac patients at two British Columbia tertiary referral hospitals[J]. Can J Cardiol,2001,17(6) : 695--704.
